Clinical trial · Interventional
Myeloid Mutations Register in R/R CML
ABL Mutation Register in Patients With ITK Relapsed or Refractory Chronic Myeloid Leukemia
NCT05080829CI-TRIAL-00054515unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of the study is to know the percentage of ABL mutations in patients with chronic myeloid leukemia that relapsed or are refractory to tyrosine-kinase inhibitors measured with a myeloid mutations panel by NGS.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Chronic Myeloid Leukaemia Recurrent | — | UNRESOLVED | — |
| Chronic Myeloid Leukemia, in Relapse | Chronic Myeloid Leukemia, BCR-ABL1 Positive | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Myeloid mutations measurement | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Mutation Register
- description
- Measure of myeloid mutations after detection of relapse or refractoriness to ITK treatment
- interventionNames
- Diagnostic Test: Myeloid mutations measurement
Primary outcomes (1)
- measure
- Presence of myeloid mutations by Next Generation Sequence
- timeFrame
- 1 year
- description
- Detection of positive myeloid mutations at detection of relapse or refractoriness to ITK treatment
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * CML diagnosis by the WHO 2016 criteria * Failure to reach cytogenetic response of Ph chromosome of 36 to 95% at 3 months or BCR/ABL \<10% at 6 months of treatment with TKI * Progression or relapse of the disease after previous response to treatment with TKI * Validation of adherence to treatment * Inform consent Exclusion Criteria: * Lack of information to complete the register * Failure to response achievement due lack of adherence to treatment
References
Publications (0)
Data not yet available
No reference posted for this study.